Mainz Biomed Bv Stock Performance

MYNZ Stock  USD 6.65  0.32  4.59%   
Mainz Biomed holds a performance score of 9 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -29.17, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Mainz Biomed are expected to decrease by larger amounts. On the other hand, during market turmoil, Mainz Biomed is expected to outperform it. Use Mainz Biomed BV jensen alpha, potential upside, accumulation distribution, as well as the relationship between the treynor ratio and expected short fall , to analyze future returns on Mainz Biomed BV.

Risk-Adjusted Performance

9 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Mainz Biomed BV are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Mainz Biomed showed solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
2.66
Five Day Return
(0.13)
Year To Date Return
495.79
Ten Year Return
(30.22)
All Time Return
(30.22)
Last Split Factor
1:40
Last Split Date
2024-12-03
1
Mainz Biomed stock plunges to 52-week low of 0.21 - Investing.com
09/23/2024
2
Mainz Biomed Publishes CEO Statement CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
10/01/2024
3
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
10/08/2024
4
Mainz Biomed B.V. GAAP EPS of -0.49, revenue of 520.77M
10/21/2024
5
Healthcare Giant Thermo Fisher Scientific Inc. Inks Deal With Mainz Biomed To Develop And Commercialize Next Gen Colorectal Cancer Screening
11/12/2024
6
Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test
11/21/2024
7
Mainz Biomed Announces Stock Split
11/29/2024
8
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
12/03/2024
Begin Period Cash Flow17.1 M
Free Cash Flow-23.8 M
  

Mainz Biomed Relative Risk vs. Return Landscape

If you would invest  35.00  in Mainz Biomed BV on September 10, 2024 and sell it today you would earn a total of  630.00  from holding Mainz Biomed BV or generate 1800.0% return on investment over 90 days. Mainz Biomed BV is currently generating 14.8107% in daily expected returns and assumes 124.4035% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Mainz, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Mainz Biomed is expected to generate 171.76 times more return on investment than the market. However, the company is 171.76 times more volatile than its market benchmark. It trades about 0.12 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.19 per unit of risk.

Mainz Biomed Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Mainz Biomed's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mainz Biomed BV, and traders can use it to determine the average amount a Mainz Biomed's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.1191

Best PortfolioBest EquityMYNZ
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative Returns

Estimated Market Risk

 124.4
  actual daily
96
96% of assets are less volatile

Expected Return

 5.01
  actual daily
96
96% of assets have lower returns

Risk-Adjusted Return

 0.12
  actual daily
9
91% of assets perform better
Based on monthly moving average Mainz Biomed is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mainz Biomed by adding it to a well-diversified portfolio.

Mainz Biomed Fundamentals Growth

Mainz Stock prices reflect investors' perceptions of the future prospects and financial health of Mainz Biomed, and Mainz Biomed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mainz Stock performance.

About Mainz Biomed Performance

Evaluating Mainz Biomed's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Mainz Biomed has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Mainz Biomed has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 580.52  609.55 
Return On Tangible Assets(2.19)(2.30)
Return On Capital Employed(4.32)(4.10)
Return On Assets(1.71)(1.79)
Return On Equity(8.09)(7.69)

Things to note about Mainz Biomed BV performance evaluation

Checking the ongoing alerts about Mainz Biomed for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mainz Biomed BV help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Mainz Biomed BV is way too risky over 90 days horizon
Mainz Biomed BV appears to be risky and price may revert if volatility continues
Mainz Biomed BV has high likelihood to experience some financial distress in the next 2 years
Mainz Biomed BVhas  3,566,004  shares shorted by Mainz Biomed investors is about 100% of outstending shares
The company reported the previous year's revenue of 895.48 K. Net Loss for the year was (26.3 M) with profit before overhead, payroll, taxes, and interest of 177.62 K.
Mainz Biomed BV currently holds about 26.01 M in cash with (21.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8.
Mainz Biomed BV has a frail financial position based on the latest SEC disclosures
Latest headline from benzinga.com: Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
Evaluating Mainz Biomed's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Mainz Biomed's stock performance include:
  • Analyzing Mainz Biomed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mainz Biomed's stock is overvalued or undervalued compared to its peers.
  • Examining Mainz Biomed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Mainz Biomed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mainz Biomed's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Mainz Biomed's stock. These opinions can provide insight into Mainz Biomed's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Mainz Biomed's stock performance is not an exact science, and many factors can impact Mainz Biomed's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Mainz Stock Analysis

When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.